Orvida Pharma is an Israeli clinical-stage biotech developing disease-modifying therapies for rare, severe genetic skin diseases. Its oral and topical TRPV3 inhibitor platform, led by ontivatrep, targets conditions such as Olmsted syndrome, palmoplantar keratoderma and ichthyosis.